Review anchor
Casein kinase II
PROTEIN COMPLEX GROUP · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Casein kinase II
CHEMBL2095191
PROTEIN COMPLEX GROUP
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Casein kinase II as ChEMBL target CHEMBL2095191, mapped to UniProt P67870. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2095191
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P67870
Casein kinase II subunit beta
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Casein kinase II matters
Casein kinase II is reviewed as Casein kinase II subunit beta (UniProt P67870); the current evidence base includes 0 approved drugs, 916 compounds, and 212 assays, with lead potency reaching pChEMBL 9.4.
Protein context
Casein kinase II subunit beta
Casein kinase II subunit beta Sequence length is 215 aa.
Review this target as Casein kinase II, mapped to UniProt P67870. ChEMBL maps the protein component as Casein kinase II subunit beta. Sequence length is 215 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P67870
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 916 compounds, and 212 assays for this target. The dominant activity type is IC50. CHEMBL1230165 is the current potency anchor at pChEMBL 9.4.
Use CHEMBL1230165 as the tractability anchor when discussing potency (pChEMBL 9.4).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 9.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Casein kinase II matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P67870, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
916
Total Compounds
212
Total Assays
0
Approved Drugs
IC50: 571.0, KI: 53.0, EC50: 2.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1230165
|
9.4 | Ki | Clinical |
|
|
No preferred name
CHEMBL1230165
|
9.0 | IC50 | Clinical |
|
|
No preferred name
CHEMBL1652710
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL3103191
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL2409175
|
8.7 | IC50 | — |
Source Header